Resumo

QUINAPANTA CASTRO, Néstor Israel; NAVARRO TAPIA, Elisabet  e  MOLINA SALCEDO, Arianna Lilibeth. Uso de cannabinoides en el tratamiento de síntomas neuropsiquiátricos de la demencia: revisión sistemática. Rev Eug Esp [online]. 2023, vol.17, n.2, pp.89-105. ISSN 2661-6742.  https://doi.org/10.37135/ee.04.17.10.

Dementia is a progressive neurodegenerative disorder that produces associated neuropsychiatric symptoms (NTS). A systematic review of clinical trials published in PubMed and Web of Science between 1996 and 2022 was conducted using the PRISMA methodology. Seven articles met the established requirements at the end of the screening process. The results of five reviewed studies confirmed a reduction in NTS. No serious adverse events were reported in any of the studies, with only mild and moderate ones. The analyzed results did not allow for establishing significant differences in favor of cannabinoids. It was impossible to identify a standardization of the dose of cannabinoids in the treatment of NTS. In the other hand, a reduction in the neuropsychiatric scales was observed when using nabilone doses of 1-2 mg/day.

Palavras-chave : Dementia; Cannabinoids; Medical Marijuana.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )